Advertisement

Anthracyclines and Anthracenediones in the Management of Breast Cancer

  • J. A. Neidhart

Abstract

Anthracyclines have now been used for treatment of breast cancer for almost two decades. The goal of prolonged life of good quality remains elusive for most women with cancer of the breast although our ability to palliate has improved greatly. We have learned a great deal, but much remains to be done. The anthracyclines continue to play a major role as new therapeutic approaches are developed. This chapter is not intended as a comprehensive review of the literature relating to anthracyclines and breast cancer. An attempt will be made to examine the state of the art and evolving treatment principles. In the interest of brevity and focus, representative works have been selected to support positions. Randomized studies are used preferentially if available. Apologies are due to the many fine investigations not mentioned that have contributed substantially to our present knowledge.

Keywords

Breast Cancer Clin Oncol Metastatic Breast Cancer Advanced Breast Cancer Dose Intensity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ahmann FR, Pugh R (1987) Short-term chemotherapy of poor-prognosis metastatic breast cancer with three non-cross resistant chemotherapy regimens. A Southwest Oncology Group study. Cancer 59: 239–244PubMedCrossRefGoogle Scholar
  2. 2.
    Aisner J, Weinberg V, Perloff M, Weiss R, Perry M, Korzun A, Ginsberg S, Holland JF (1987) Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each±MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol 5: 1523–1533PubMedGoogle Scholar
  3. 3.
    Allegra JC, Woodcock T, Woolf S, Henderson IC, Bryan S, Reisman A, Dukart G (1985) A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. Invest New Drugs 3: 153–161PubMedCrossRefGoogle Scholar
  4. 4.
    Armand JP, Hurteloup P, Hayat M, Chauvergne J, Fargeot P, Schraub S (1984) Phase III chemotherapy comparing FAC vs FEC in advanced breast cancer: preliminary results. Proc Am Soc Clin Oncol 3: 118Google Scholar
  5. 5.
    Baretta G, Locatelli C, Tabiadon D, Labianca R, Fraschini P, Luporini G (1987) Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen. Oncology 44: 6–12CrossRefGoogle Scholar
  6. 6.
    Bennett JM, Byrne P, Desai A, White C, DeConti R, Vogel C, Krementz E, Muggia F, Doroshow J, Plotkin D, Golomb H, Muss H, Brodovsky H, Gams R, Horgan LR, Bryant S, Weiss A, Cartwright K, Dukart G (1985) A randomized multicenter trial of cyclophosphamide, novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Invest New Drugs 3: 179–185PubMedCrossRefGoogle Scholar
  7. 7.
    Boyages J (1986) The problem of local control in patients with advanced breast cancer - a combined modality approach. Australas Radiol 30: 60–62PubMedCrossRefGoogle Scholar
  8. 8.
    Brambilla C, De Lena M, Rossi A, Valagussa P, Bonadonna G (1976) Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J 1: 801–804PubMedCrossRefGoogle Scholar
  9. 9.
    Brambilla C, Rossi A, Bonfante V, Ferrari L, Villani F, Crippa F, Bonadonna G (1986) Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70: 261–266PubMedGoogle Scholar
  10. 10.
    Brun B, Otmezguine Y, Feuilhade F, Julien M, Lebourgeois JP, Calitchi E, Roucayrol AM, Ganem G, Huart J, Pierguin B (1988) Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer 61: 1096–1103PubMedCrossRefGoogle Scholar
  11. 11.
    Bull JM, Tormey DC, Li S-H, Carbone PP, Falkson G, Blom J, Perlin E, Simon R (1978) A randomized comparative trial of Adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649–1657PubMedCrossRefGoogle Scholar
  12. 12.
    Carmo-Pereira J, Costa FO, Henriques E (1981) Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP). Cancer 48: 1517–1521PubMedCrossRefGoogle Scholar
  13. 13.
    Carmo-Pereira J, Costa FO, Henriques E, Godinho F, Cantinho-Lopes MG, Sales-Luis A, Rubens RD (1987) A comparison of two doses of Adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56: 471–473PubMedCrossRefGoogle Scholar
  14. 14.
    Chlebowski RT, Paroly WS, Pugh RP, Hueser J, Jacobs EM, Pajak TF, Bateman JR (1980) Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64: 47–51PubMedGoogle Scholar
  15. 15.
    Coates A, Bebski V, Stat M, Bishop JF, Jeal PN, Woods RL, Snyder R, Tattersall MHN, Byrne M, Harvey V, Gill G, Simpson J, Drummond R, Browne J, van Cooten R, Forges JF (1987) Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med 317: 1490–1495PubMedCrossRefGoogle Scholar
  16. 16.
    Coombes RC, Dady P, Parsons C, McCready VR, Ford HT, Gazet J-C, Powles TJ (1983) Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer 57: 610–614CrossRefGoogle Scholar
  17. 17.
    Cummings FJ, Gelman R, Horton J (1985) Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol 3: 932–940PubMedGoogle Scholar
  18. 18.
    De Lena M, Varini M, Zucali R, Rovini D, Viganotti G, Valagussa P, Veronesi U, Bonadonna G (1981) Multimodal treatment for locally advanced breast cancer. Cancer Clin Trials 4: 229–236PubMedGoogle Scholar
  19. 19.
    De Lena M, Zucali R, Viganotti G et al. (1978) Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1: 53–59PubMedCrossRefGoogle Scholar
  20. 20.
    Ghilchik M, Shaikh NA, Beranek PA, Reed MJ (1987) Cyclical sequential hormonochemotherapy in advanced breast cancer. Br Med J 295: 1172CrossRefGoogle Scholar
  21. 21.
    Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733PubMedGoogle Scholar
  22. 22.
    Gundersen S, Kvinnsland S, Klepp O, Kvaloy S, Lund E, Host H (1986) Weekly Adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 22 (2): 1431–1434PubMedCrossRefGoogle Scholar
  23. 23.
    Hart RD, Perloff M, Holland JF (1981) One-day VATH (vinblastine, Adriamycin, thiotepa, and Halotestin) therapy for advance breast cancer refractory to chemotherapy. Cancer 48: 1522–1527PubMedCrossRefGoogle Scholar
  24. 24.
    Henderson IC, Gelman R, Canellos GP, Frei III E (1981) Prolonged disease-free survival in advanced breast cancer treated with “super-CMF” Adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep 65 (Suppl 1): 67–75PubMedGoogle Scholar
  25. 25.
    Henderson IC, Wolff S, Allegra J, Grace W, Spicer D, Bryan S, Reisman A, Dukart G (1985) Mitoxantrone (M) vs doxorubicin (DOX) in advanced breast cancer (BC): a randomized trial in 220 patients (PTS). Proc Am Soc Clin Oncol 4: 62Google Scholar
  26. 26.
    Hoogstraten B, George SL, Samal B, Rivkin SE, Costanzi JJ, Bonnet JD, Thigpen T, Braine H (1976) Combination chemotherapy and Adriamycin in patients with advanced breast cancer. Cancer 38: 13–20PubMedCrossRefGoogle Scholar
  27. 27.
    Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, Schell F (1983) Multimodal treatment of locoregionally advanced breast cancer. Cancer 51: 763–768PubMedCrossRefGoogle Scholar
  28. 28.
    Hortobagyi G, Yap HY, Aboud A, Kau S, Franschini G, Buzdar A, Blumenschein G (1984) Doxorubicin (D) vs 4’-epidoxorubicin (4ED) for metastatic breast cancer (MBC): a prospective randomized study. Proc Am Soc Clin Oncol 3: 121Google Scholar
  29. 29.
    Hortobagyi GN, Buzdar AU, Bodey GP, Kau S, Rodriquez V, Legha SS, Yap HY, Blumenschein GR (1987) High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol 5: 178–184PubMedGoogle Scholar
  30. 30.
    Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281–1288PubMedGoogle Scholar
  31. 31.
    Jain KK, Wittes R, Benedetto P, Kaufman R, Currie V, Hakes T, Bosl G (1983) A randomized comparison of weekly (arm I) vs monthly (arm II) doxorubicin (DOX) in combination with mitomycin-C (MMC) in advanced breast cancer. Proc Am Soc Clin Oncol 2: 109Google Scholar
  32. 32.
    Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, Schwartz W, Cassidy C, Petroni GR, Young CW, Wittes RE (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3: 818–826PubMedGoogle Scholar
  33. 33.
    Jones WG, Mattsson W (1984) Phase II study of weekly low-dose 4’-epi-doxorubicin in advanced postmenopausal breast cancer. Cancer Treat Rep 68: 675–677PubMedGoogle Scholar
  34. 34.
    Jones RB, Holland JF, Bhardway S, Norton L, Wilfinger C, Strashun A (1987) A phase I–II study of intensive-dose Adriamycin for advanced breast cancer. J Clin Oncol 5: 172–177PubMedGoogle Scholar
  35. 35.
    Leonard RCF, Cornbleet MA, Kaye SB, Soukop M, White G, Hutcheon AW, Robinson S, Kerr ME, Smyth JF (1987) Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. J Clin Oncol 5: 1056–1063PubMedGoogle Scholar
  36. 36.
    Lokich JJ, Zipoli TE, Moore C, Sonneborn H, Paul S, Greene R (1986) Doxorubicin/vinblastine and doxorubicin/cyclophosphamide combination chemotherapy by continuous infusion. Cancer 58: 1020–1023PubMedCrossRefGoogle Scholar
  37. 37.
    Malik R, Blumenschein GR, Legha SS, Hortobagyi GN, Buzdar A, Yap HY, Hill S, Bodey GP (1982) A randomized trial of high dose 5-fluorouracil (F), doxorubicin (A) and cyclophosphamide (C) vs conventional FAC regimen in metastatic breast cancer. Proc Am Soc Clin Oncol 1: 79Google Scholar
  38. 38.
    Mathe G, Plagne R, Morice V, Misset (1987) Consistencies and variations of observations during serial analyses of a trial of adjuvant chemotherapy in breast cancer. In: Salmon SE (ed) Adjuvant therapy of cancer V. Grune and Stratton, Orlando, pp 271–280Google Scholar
  39. 39.
    Mattsson W, Borgstrom S, Landberg T (1982) A weekly schedule of low-dose doxorubicin in treatment of advanced breast cancer. Clin Ther 5 (2): 193–203PubMedGoogle Scholar
  40. 40.
    Neidhart JA, Gochnour D, Roach RW, Steinberg JA, Young D (1983) Mitoxantrone versus doxorubicin in advanced breast cancer: a randomized cross-over trial. Cancer Treat Rev 10 (B): 41–46PubMedCrossRefGoogle Scholar
  41. 41.
    Nemoto T, Horton J, Simon R, Dao TL, Rosner D, Cunningham T, Sponzo R, Snyderman M (1982) Comparison of four combination chemotherapy programs in metastatic breast cancer. Cancer 49: 1988–1993PubMedCrossRefGoogle Scholar
  42. 42.
    Noguchi S, Miyauchi K, Nishizawa Y, Koyama H, Terasawa T (1988) Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as an induction therapy. Cancer 61: 1483–1491PubMedCrossRefGoogle Scholar
  43. 43.
    Patel JK, Nemoto T, Vezeridis M, Petrelli N, Suh O, Dao TL (1986) Does more intense palliative treatment improve overall survival in metastatic breast cancer patients? Cancer 57: 567–570PubMedCrossRefGoogle Scholar
  44. 44.
    Perez CA, Presant C, Philpott G, Ratkin G (1979) Phase I-II study of concurrent irradiation and multi-drug chemotherapy in advanced carcinoma of the breast: a pilot study by the Southeastern Cancer Study Group. Int J Radiat Oncol Biol Phys 5: 1329–1333PubMedGoogle Scholar
  45. 45.
    Perloff M, Norton L, Korzun A, Wood W, Carey R, Weinberg V, Holland JF (1986) Advantage of an Adriamycin (A) combination plus Halotestin (H) after initial cyclo¬phosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) for adjuvant therapy of node-positive stage II breast cancer. Proc Am Soc Clin Oncol 5: 70Google Scholar
  46. 46.
    Perry MC, Kardinal CG, Korzun AH, Ginsberg SJ, Raich PC, Holland JF, Ellison RR, Kopel S, Schilling A, Aisner J, Schulman P, Weinberg V, Rice MA, Wood W (1987) Chemohormonal therapy in advanced carcinoma of the breast: cancer and leukemia group B protocol 8081. J Clin Oncol 5: 1534–1545PubMedGoogle Scholar
  47. 47.
    Scheithauer W, Zielinksi C, Ludwig H (1985) Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment. Breast Cancer Res Treatment 6: 89–93CrossRefGoogle Scholar
  48. 48.
    Sigurdsson H, Johansson-Terje I, Aspergren K, Landberg T, Andersson Borgstrom S, Thelin A-M (1986) Weekly-dose doxorubicin (WDA) in advanced breast cancer. Radiother Oncol 7: 133–139PubMedCrossRefGoogle Scholar
  49. 49.
    Smalley RV, Carpenter J, Bartolucci A, Vogel C, Krauss S (1977) A comparison of cyclophosphamide, Adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. Cancer 40: 625–632PubMedCrossRefGoogle Scholar
  50. 50.
    Tormey DC, Falkson G, Simon RM, Blom J, Bull JM, Lippman ME, Li S-H, Cassidy JG, Falkson HC (1979) A randomized comparison of two sequentially administered combination regimens to a single regimen in metastatic breast cancer. Cancer Clin Trials 2: 247–256Google Scholar
  51. 51.
    Tormey DC, Gelman R, Band PR, Sears M, Rosenthal SN, DeWys W, Perlia C, Rice MA (1982) Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group trial. Cancer 50: 1235–1244PubMedCrossRefGoogle Scholar
  52. 52.
    Tormey D, Gelman R, Falkson G (1983) Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group trial. Am J Clin Oncol 6: 1–18PubMedGoogle Scholar
  53. 53.
    Tormey DC, Weinberg VE, Leone LA, Glidewell OJ, Perloff M, Kennedy BJ, Cortes E, Silver RT, Weiss RB, Aisner J, Holland JF (1984) A comparison of intermittent vs continuous and of Adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer. Am J Clin Oncol 7: 231–239PubMedCrossRefGoogle Scholar
  54. 54.
    Tormey DC, Kline JC, Palta M, Davis TE, Love RR, Carbone PP (1985) Short term high density systemic therapy for metastatic breast cancer. Breast Cancer Res Treat 5: 177–188PubMedCrossRefGoogle Scholar
  55. 55.
    Vogel CL, Smalley RV, Raney M, Krauss S, Carpenter J, Velez-Garcia E, Fishkin E, Raab S, Moore MR, Stagg M (1984) Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a “cycle active” non-cross- resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. J Clin Oncol 2: 643–651PubMedGoogle Scholar
  56. 56.
    Wittes R, Jain K, Kaufman R, Currie V, Hakes T, Bosl G, Benedetto P, Young C (1983) A randomized comparison of 4’-epidoxorubicin (4’ED) and doxorubicin (DOX) in advanced breast cancer. Proc Am Soc Clin Oncol 2: 109Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1991

Authors and Affiliations

  • J. A. Neidhart
    • 1
  1. 1.University of New Mexico Cancer CenterN.E. AlbuquerqueUSA

Personalised recommendations